Erythrocyte sedimentation rate and albumin as markers of inflammation are associated with measures of sarcopenia: a cross-sectional study

Vera A. van Atteveld¹, Jeanine M. Van Ancum¹, Esme M. Reijnierse², Marijke C. Trappenburg³,⁴, Carel G. M. Meskers¹,⁵ and Andrea B. Maier¹,²*

Abstract

Background: Chronic inflammation is considered to affect physical performance, muscle strength and muscle mass, i.e. measures of sarcopenia. We need to identify a marker of inflammation that is univocally associated with measures of sarcopenia. We aimed to associate three markers of inflammation, erythrocyte sedimentation rate, albumin and white blood cell count, with measures of sarcopenia in geriatric outpatients.

Methods: Data from the Centre Of Geriatrics Amsterdam cohort was used. Geriatric outpatients at the VU university medical centre in Amsterdam were recruited based on referral between January 1st 2014 and the 31st of December 2015. Erythrocyte sedimentation rate, albumin and white blood cell count were assessed from venous blood samples. Measures of sarcopenia included physical performance by measuring gait speed with the 4 meter walk test, duration of the timed up and go test and of the chair stand test, muscle strength by assessing handgrip strength using handheld dynamometry and skeletal muscle mass by performing bioelectrical impedance analysis. Multivariable linear regression analyses were performed to assess the associations between erythrocyte sedimentation rate, albumin, white blood cell count and measures of sarcopenia.

Results: A total of 442 patients (mean age 80.8 years, SD 6.7, 58.1% female) were included. A higher erythrocyte sedimentation rate was significantly associated with lower gait speed (β = −0.005; 95% CI = −0.007, −0.003), longer duration of timed up and go test (Ln β = 0.006; 95% CI = 0.003, 0.010), longer duration of chair stand test (Ln β = 0.005; 95% CI = 0.002, 0.008), lower handgrip strength (β = −0.126; 95% CI = −0.189, −0.063) and lower relative skeletal muscle mass (β = −0.179; 95% CI = −0.274, −0.084). Lower albumin levels were significantly associated with lower gait speed (β = −0.020; 95% CI = −0.011, −0.028) and handgrip strength (β = −0.596; 95% CI = −0.311, −0.881). Associations remained significant after adjustment for age, sex and number of morbidities. No significant associations were found for white blood cell count and measures of sarcopenia.

(Continued on next page)
Background
Sarcopenia, low physical performance, muscle strength and muscle mass, recently redefined by the European Working Group on Sarcopenia in Older People (EWG-SOP2) [1], is a highly prevalent disease ranging up to 15% in older persons of 60 to 70 years old, and between 40 to 50% in individuals of 80 years and older [2, 3]. Sarcopenia is associated with impaired functional status [4], which is related to adverse health outcomes such as nursing home admission and mortality [5]. Many factors have been identified that are involved in the pathophysiology of sarcopenia, such as malnutrition, hormonal changes (lower levels of growth hormone and sex hormones), physical inactivity and chronic inflammation [6].

Inflammation is thought to be an important risk factor for sarcopenia, as it induces a catabolic state in the muscles [7]. Inflammatory markers that have been investigated in relation to sarcopenia showed contradicting results, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), albumin, white blood cell (WBC) count, cytokines (e.g. Tumor Necrosis Factor-α (TNF-α), Interleukine-6 (IL-6)) and its soluble receptors [8–16], TNF-α, IL-6, CRP, albumin, WBC count and ESR were found to be associated with low physical performance, muscle strength or muscle mass in older people [8, 9, 13, 14, 16], but other studies failed to find this association [10, 11, 13, 17]. To date, TNF-α, IL-6, albumin and CRP have shown a relation with the development of low muscle strength or muscle mass over time [8, 13–15], however, the current body of evidence fails to reveal a marker of chronic inflammation that is univocally associated with measures of sarcopenia in older people [18, 19].

The aim of the present paper is to associate ESR, albumin and WBC count as markers of inflammation, with measures of sarcopenia i.e. physical performance, muscle strength and muscle mass in a cohort of geriatric outpatients. The number of studies evaluating geriatric outpatients is limited.

Methods
Study design
The Centre Of Geriatrics Amsterdam (COGA) cohort encompasses 572 patients who were referred to the geriatric outpatient clinic of the VU University Medical Center in Amsterdam, the Netherlands, between January 1st 2014 and the 31st of December 2015. Study inclusion was based on referral by general practitioners due to either mobility, cognitive problems or functional decline. A comprehensive geriatric assessment was performed by a geriatric nurse, including measurements of physical and cognitive performance. The assessment was followed by a consultation of a geriatrician. Blood samples were collected in 505 patients, of which ESR, albumin or WBC count and at least one physical test were available in 442 patients. No exclusion criteria were applied. The Medical Ethical Committee of the VU University Medical Center approved the study (reference number 2017.582). As this cross-sectional study was based on regular care, the need for individual informed consent was waived.

Patient characteristics
Relevant characteristics such as age, sex, living status, education, alcohol use, smoking, medication use, medical history, cognitive status, weight, height and functional status were obtained in the abovementioned comprehensive geriatric assessment. Use of anti-inflammatory medication was defined as the use of prednisone, prednisolone, methotrexate, mesalazine, hydroxychloroquine, infliximab or non-steroid anti-inflammatory drugs (NSAID). Medical history that was counted as morbidities included angina, dementia, depression, diabetes type 1 or 2, heart failure, hypercholesterolemia, hypertension, hyperthyroidism, hypothyroidism, malignancy, myocardial infarction, renal insufficiency, osteoporosis, Parkinson’s disease, transient ischemic attack (TIA), cerebral infarction, arrhythmias, joint prosthesis, joint disease or obstructive pulmonary disease. Cognitive status was tested using the mini-mental state examination (MMSE) [20]. Functional status included independency in activities of daily living (ADL) measured by the Katz index [21] with a higher score indicating more dependency, use of a walking aid, immobility for more than 1 week in the preceding 3 months, maximal walking distance and experiencing a fall in the preceding year. Hemoglobin level in mmol/L was measured by the Sodium Lauryl Sulphate (SLS) detection method. SLS binds with heme, causing a color change that is measured photometrically (Sysmex XN9000, Sysmex BV, Etten-Leur, the Netherlands).
Inflammatory markers
ESR in millimeter/hour (mm/hr) was measured using non-hemolyzed EDTA-anticoagulated whole blood that was analyzed following the Westergren method (StaRRsed Auto Compact VERA109900, Mechatronics BV, Hoorn, the Netherlands). The Westergren method is the reference method of the International Council for Standardization in Hematology (ICSH) [22].

Albumin in g/L was measured in serum using a colorimetric test with brom cresol purple. Brom cresol purple binds selectively with albumin and the color change is measured photometrically (Cobas 8000 modular analyzer series, Roche Netherlands BV, Woerden, the Netherlands).

WBC count in E 9/L was measured using non-hemolyzed EDTA-anticoagulated whole blood with fluorescence flow cytometry (Sysmex XN9000, Sysmex BV, Etten-Leur, the Netherlands).

Measures of sarcopenia
Gait speed was assessed by the 4 meter walk test at usual pace [23], and expressed in meters/second (m/s). The timed up and go (TUG) test as a measure of functional mobility [24], and the chair stand test (CST) as an indicator of lower limb strength [25] were both expressed in seconds (s).

Handgrip strength (HGS) was measured by a hand dynamometer in a standing position with a stretched arm (angle of 180 degrees) (Jamar hand dynamometer, Sammons Preston, Inc., Bolingbrook, IL) and expressed in kilograms (kg). Maximal handgrip strength out of six attempts (three left and three right) was used [26].

Muscle mass was measured in a standing position using direct segmental multi-frequency bioelectrical impedance analysis (DSM-BIA; InBody 720; Biospace Co., Ltd., Seoul, Korea), which is a validated tool to assess body composition [27]. Patients with a pacemaker or defibrillator were excluded from this measurement. Two parameters were extracted from the DSM-BIA measurements: relative skeletal muscle mass (RMM) in percent calculated as [skeletal muscle mass in kg/weight*100] and appendicular lean mass (ALM) divided by height 2 in kg/m 2 calculated as [ALM/height 2]. DSM-BIA measurements were available in 68 patients as these measurements were added to the comprehensive geriatric assessment in a later stage of the inclusion period.

Statistical analyses
For normally distributed variables, mean values and standard deviations (SD) were presented, for skewed variables medians and interquartile ranges (IQR), and for categorical variables the number and percentage. The associations between the independent variables (ESR, albumin and WBC count) and the dependent variables (measures of sarcopenia) were analyzed using multivariable linear regression. Results were presented as β with 95% confidence intervals (95% CI) and p values; significance level was set at α = 0.05. Skewed variables (TUG test and CST), were log-transformed using the natural logarithm. The log-transformed β can be interpreted as follows: [(e^β – 1) * 100] equals the percentage of change in the dependent variable with every unit increase of the independent variable. Age, sex and number of morbidities were identified as possible confounders. An additional sensitivity analysis was performed, excluding patients who used anti-inflammatory medication (n = 36). A second additional analysis was performed, comparing ESR, albumin levels and WBC count for patients with low or normal measures of sarcopenia based on the EWGSOP2 definition cut-off points, using logistic regression analyses adjusted for age, sex and number of comorbidities. For the statistical analysis, IBM SPSS statistics 25 for Windows was used. For visual presentation, ESR tertiles were calculated and bar charts were made using GraphPad Prism version 7.00 for Windows, GraphPad Software, La Jolla California USA.

Results
Patient characteristics are shown in Table 1. The mean age of the population was 80.8 years (SD: 6.7), 58.1% was female, 87.2% of the patients were living independently and the median number of morbidities was 3 (IQR: 2–4).

The associations between ESR, albumin and WBC count with physical performance are shown in Table 2. Higher ESR was significantly associated with lower gait speed and longer duration of the TUG test and CST. After adjustment for age, sex and number of morbidities, these associations remained significant. Higher ESR was significantly associated with lower HGS and lower RMM both in the crude model as well as in the adjusted model. No association was found between ESR and ALM/height 2. Lower albumin was significantly associated with lower gait speed and handgrip strength in the crude as well as in the adjusted model. No associations were found between albumin and duration of the TUG test and CST, RMM and ALM/height 2. Higher WBC count was significantly associated with lower gait speed and handgrip strength, however, after adjustment the associations were no longer significant. Figure 1 shows the tertiles of ESR with measures of sarcopenia.

Results did not change significantly when excluding patients using anti-inflammatory medication (Additional file 1: Table S1). Additional file 2: Table S2 shows the median [IQR] levels of ESR, albumin and WBC count for patients with low or normal measures of sarcopenia. ESR and albumin were different between low or normal gait speed, TUG, CST and HGS. For low or normal ALM/height 2, no significant difference was found. WBC count was not different for any of the measures of sarcopenia.
Table 1 Patient characteristics

| Characteristics                | n    | Total (n = 442) |
|-------------------------------|------|-----------------|
| General                       |      | Total (n = 442) |
| Age, years                    | 442  | 80.8 (6.7)      |
| Sex, female, n (%)            | 442  | 257 (58.1)      |
| Living independently, n (%)   | 421  | 367 (87.2)      |
| Education, years, median [IQR]| 380  | 10 [9–13]       |
| Use of alcohol, n (%)          | 408  | 255 (62.5)      |
| Current smoking, n (%)         | 410  | 43 (10.5)       |
| Polypharmacy, n (%)*           | 441  | 257 (58.3)      |
| Anti-inflammatory medication, n (%)†| 440 | 36 (8.2)        |
| Number of morbidities, median [IQR]| 441 | 3 [2–4]         |
| MMSE score, median [IQR]      | 425  | 26 [22–28]      |
| Weight, kg                    | 413  | 70.2 (13.5)     |
| Height, cm                    | 414  | 166.6 (9.7)     |
| BMI, kg/m²                    | 408  | 25.3 (4.2)      |
| Hemoglobin, mmol/L            | 435  | 8.6 (0.9)       |
| Anemia, n (%)                 | 435  | 83 (19.1)       |
| Functional status             |      | Total (n = 442) |
| Katz ADL score, median [IQR]  | 399  | 0 [0–1]         |
| Use of walking aid, n (%)     | 408  | 169 (41.4)      |
| Immobile > 1 week in last 3 months, n (%) | 387 | 59 (15.2) |
| Maximal walking distance, > 1 km, n (%) | 391 | 140 (35.8) |
| Fall in past year, n (%)      | 404  | 246 (60.9)      |
| Inflammatory markers          |      | Total (n = 442) |
| ESR, mm/hr., median [IQR]     | 408  | 11 [6–22]       |
| Albumin, g/L, median [IQR]    | 433  | 37.8 [35.7–39.7]|
| WBC count, E^3/L, median [IQR]| 442  | 7.2 [6.0–8.7]   |
| Measures of sarcopenia        |      | Total (n = 442) |
| Gait speed, m/s               | 419  | 0.8 (0.3)       |
| TUG test, s, median [IQR]     | 303  | 14.9 [11.5–19.0]|
| CST, s, median [IQR]          | 356  | 13.6 [11.4–18.6]|
| HGS, kg                       | 423  | 22.2 (9.6)      |
| RMM, %                        | 68   | 36.7 (5.4)      |
| ALM/height², kg/m²            | 68   | 7.1 (1.2)       |

All variables are presented as mean (standard deviation), unless otherwise specified

ADL Activities of daily living, ALM Appendicular lean mass, BMI Body mass index, CST Chair stand test, ESR Erythrocyte sedimentation rate, HGS Handgrip strength, IQR Interquartile range, MMSE Mini-mental state examination, RMM Relative skeletal muscle mass, TUG Timed up and go, VAS Visual analogue scale, WBC White blood cell

†Anti-inflammatory medication: use of prednisone, prednisolone, methotrexate, mesalazine, hydroxychloroquine, infliximab or non-steroid anti-inflammatory drugs

Discussion

In a cohort of geriatric outpatients higher ESR was associated with worse physical performance measured as lower gait speed, longer duration of the TUG test and CST, lower muscle strength expressed as HGS, and lower muscle mass expressed as RMM. Lower albumin was associated with lower HGS and gait speed. WBC count was not associated with any measure of sarcopenia.

A single and reliable marker for sarcopenia has not been found yet. This may be due to the many pathways that are involved in causing sarcopenia such as the endocrine pathway and the inflammation-mediated pathway that the present study examined. Inflammation can be measured using different markers, such as IL-6, TNF-α, CRP, butyryl-cholinesterase and oxidized low-density lipoprotein [28]. Results from previous studies are contradictory regarding the association of inflammatory markers and sarcopenia. ESR was found to be elevated in a sarcopenic group of 36 geriatric outpatients compared to a non-sarcopenic group of 36 geriatric outpatients [9], as well as in a group of 101 geriatric inpatients with sarcopenia compared to a non-sarcopenic group of 458 geriatric inpatients admitted to the rehabilitation ward [29]. However, in a cohort of 200 independent-living older adults, ESR was comparable between sarcopenic and healthy adults [17]. Lower albumin was associated with a decline in muscle mass after three to 5 years in community-dwelling men and women [14, 15]. Other inflammatory markers such as TNF-α, IL-6, WBC count, butyryl-cholinesterase and CRP were found to be correlated with poorer physical performance, muscle strength or muscle mass in geriatric outpatients and community-dwelling older adults [8, 13, 16, 30–32]. However, other studies failed to find an association between IL-6 and physical performance, nor confirm the findings for IL-6 and CRP and muscle strength and muscle mass in community-dwelling older people [10, 11, 13]. The current study included a broad range of measures of sarcopenia, and found that ESR is associated with three measures of physical performance (gait speed, duration of the TUG test and the CST), as well as with muscle strength and muscle mass. Albumin was found to be associated with two measures of sarcopenia: gait speed and handgrip strength.

The inverse associations between inflammatory markers and measures of sarcopenia may be explained by ageing. Ageing is associated with a state of chronic low-grade inflammation [33], the main source of pro-inflammatory molecules being adipose tissue [7]. Increased levels of inflammatory markers can lead to skeletal muscle proteolysis activation, raised insulin resistance lowering the inhibition of protein catabolism by insulin [34], and eventually atrophy of skeletal muscle [7]. This may explain why no significant associations were found for WBC count. Higher WBC count is most typically associated with acute infections rather than with chronic low grade inflammation [35], and is less commonly studied in this perspective as opposed to other makers [36].
|                      | Gait speed, m/s | Ln TUG test, s | Ln CST, s | HGS, kg | RMM, % | ALM/height², kg/m² |
|----------------------|-----------------|---------------|----------|---------|--------|-------------------|
| **ESR**              |                 |               |          |         |        |                   |
| Crude β 95% CI       | -0.005 -0.007, -0.003 | 0.006 0.003, 0.010 | 0.005 0.002, 0.008 | -0.126 -0.189, -0.063 | -0.179 -0.274, -0.084 | -0.000 -0.022, 0.022 |
| p value              | 0.000           | 0.000         | 0.001    | 0.000   | 0.000  | 1.000             |
| Adjusted β 95% CI    | -0.004 -0.006, -0.002 | 0.005 0.002, 0.008 | 0.005 0.002, 0.008 | -0.052 -0.102, -0.001 | -0.115 -0.196, -0.034 | 0.010-0.011, 0.031 |
| p value              | 0.000           | 0.002         | 0.003    | 0.046   | 0.006  | 0.328             |
| **Albumin**          |                 |               |          |         |        |                   |
| Crude β 95% CI       | 0.020 0.011, 0.028 | -0.020 -0.034, -0.006 | -0.012 -0.025, 0.001 | 0.596 0.311, 0.881 | 0.233-0.244, 0.711 | 0.002-0.101, 0.106 |
| p value              | 0.000           | 0.006         | 0.062    | 0.000   | 0.333  | 0.962             |
| Adjusted β 95% CI    | 0.014 0.006, 0.022 | -0.013 -0.027, 0.000 | -0.009 -0.022, 0.004 | 0.455 0.225, 0.684 | 0.375-0.014, 0.764 | -0.007 -0.102, 0.088 |
| p value              | 0.001           | 0.057         | 0.166    | 0.000   | 0.059  | 0.886             |
| **WBC count**        |                 |               |          |         |        |                   |
| Crude β 95% CI       | -0.011 -0.021, -0.002 | 0.011-0.005, 0.026 | 0.002-0.012, 0.016 | -0.354 -0.679, -0.029 | -0.654-1.362, 0.055 | -0.105 -0.263, 0.053 |
| p value              | 0.018           | 0.178         | 0.785    | 0.033   | 0.070  | 0.188             |
| Adjusted β 95% CI    | -0.005 -0.014, 0.004 | 0.006-0.009, 0.021 | -0.001 -0.015, 0.013 | -0.112 -0.371, 0.146 | -0.430-1.017, 0.156 | -0.071 -0.214, 0.071 |
| p value              | 0.299           | 0.409         | 0.921    | 0.393   | 0.147  | 0.322             |

*ALM Appendicular lean mass, β Beta, CI Confidence interval, CST Chair stand test, ESR Erythrocyte sedimentation rate, HGS Handgrip strength, Ln Natural logarithm, RMM Relative skeletal muscle mass, TUG Timed up and go, WBC White blood cell. Adjusted model: adjusted for age, sex, number of morbidities. Bold indicates a statistical significant outcome.*
In the current study, ESR was not significantly associated with ALM/height². On the contrary, the association with RMM, a percentage of body mass, was significant in all statistical models. In previous studies, ALM/height² and RMM are commonly used in diagnosis of sarcopenia, but there is no consensus on which measure defines low muscle mass best [3]. The significant association between ESR and RMM may reflect the tight interaction between fat mass and muscle mass in the sense that a higher fat mass leads to a chronic pro-inflammatory state which is subsequently associated with sarcopenia [37].

Strengths and limitations
Strengths of the present study were the large sample of patients in a relevant study population of geriatric outpatients, and the use of different outcome measures encompassing measures of sarcopenia. There are a few limitations to this study to report. The study samples of outpatients with muscle mass measures were small, as BIA measurements were added to the protocol in a later stage. The small sample size might have reduced the power of the associations with muscle mass. ESR, albumin and WBC count are not specific markers of chronic inflammation. ESR, albumin levels and WBC count can also change as a result of other (non-chronic) conditions. Other markers of inflammation such as CRP and butyryl-cholinesterase were not available in our database, therewith the analyses were limited to ESR, albumin and WBC count [28, 32]. Furthermore, the cross-sectional study design cannot prove causality, so our findings need to be confirmed in a longitudinal study.

Conclusions
In summary, in a cohort of geriatric outpatients, ESR, a marker of chronic inflammation, was associated with all
three measures of sarcopenia: physical performance, muscle strength and muscle mass. Albumin was associated with handgrip strength and gait speed. No associations were found for WBC count. These results underpin a role of chronic inflammation in sarcopenia in geriatric outpatients, a population that has not been extensively studied to date.

Additional files

Additional file 1: Table S1. Outcomes of linear regression analyses of the associations between ESR, albumin and WBC count with measures of sarcopenia, without patients who use anti-inflammatory medication. (DOCX 15 kb)

Additional file 2: Table S2. ESR, albumin and WBC count compared for cut-off points for measures of sarcopenia according to EWGSOP 2. (DOCX 16 kb)

Abbreviations
ADL: Activities of daily living; ALM: Appendicular lean mass; Cl: Confidence interval; COGA: Centre of geriatrics Amsterdam; CRP: C-reactive protein; CST: Chair stand test; DSM-BIA: Direct segmental multi-frequency bioelectrical impedance analysis; ESR: Erythrocyte sedimentation rate; HGS: Handgrip strength; IC: International council for standardization in hematology; IL-6: Interleukine-6; IQR: Interquartile range; MMSE: Mini-mental state examination; NSAID: Non-steroid anti-inflammatory drugs; RMW: Relative skeletal muscle mass; SD: Standard deviation; TIA: Transient ischemic attack; TNG-α: Tumor necrosis factor α; TUG: Timed up and go; WBC: White blood cell

Acknowledgements
Not applicable.

Authors’ contributions
Conceived the study protocol and design: VAVA, JMVA, CGMM and ABM. Collected data: EMR, MCT, CGMM and ABM. Analyzed the data: VAVA and LVA. Contributed to analyses: EMR, MCT, CGMM and ABM. Conceived the study protocol and design: VAVA, JMVA, CGMM and ABM.

Funding
This study was supported by the European Union’s Horizon 2020 research and innovation programme (No 689238 and No 675003). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The Medical Ethical Committee of the VU University Medical Center approved the study (reference number 2017.582). As this cross-sectional study was based on regular care, the need for individual informed consent was waived.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Human Movement Sciences, @AgeAmsterdam, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, The Netherlands. 2Department of Medicine and Aged Care, @AgeMelbourne, The Royal Melbourne Hospital, The University of Melbourne, Centre for Medical Research building, Melbourne, 300 Grattan Street, Parkville, Victoria 3010, Australia. 3Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands. 4Department of Internal Medicine, Amstelland Hospital, Amstelveen, The Netherlands. 5Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam Movement Sciences, Amsterdam, The Netherlands.

Received: 25 November 2018 Accepted: 20 August 2019

References
1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.
2. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;137:555–63.
3. Rejnérse EM, Trappenburg MC, Leter M, et al. The impact of different diagnostic criteria on the prevalence of sarcopenia in healthy elderly participants and geriatric outpatients. Gerontology. 2015;61:491–6.
4. Foldvari M, Clark M, Lavolette LC, et al. Association of Muscle Power with Functional Status in community-dwelling elderly women. J Gerontol A Biol Sci Med Sci. 2000;55:M119–M2.
5. Carey EC, Walter LC, Lindquist K, et al. Development and validation of a functional morbidity index to predict mortality in community-dwelling elders. J Gen Intern Med. 2004;19:1027–33.
6. Ziaaldini MM, Marzetti E, Picca A, et al. Biochemical Pathways of Sarcopenia and Their Modulation by Physical Exercise. A Narrative Review. Front Med (Lausanne). 2017;4:167.
7. Xia Z, Cholewa J, Zhao Y, et al. Targeting inflammation and downstream protein metabolism in sarcopenia: a brief up-dated description of concurrent exercise and leucine-based multimodal intervention. Front Physiol. 2017;8:434.
8. Alemán H, Esparza J, Ramírez FA, et al. Longitudinal evidence on the association between interleukin-6 and C-reactive protein with the loss of total appendicular skeletal muscle in free-living older men and women. Age Ageing. 2011;40:69–75.
9. Gan B, Kara O, Kottaraslanoglu MC, et al. Serum markers of inflammation and oxidative stress in sarcopenia. Aging Clin Exp Res. 2017;29:745–52.
10. Felicio DC, Pereira DS, Assumpção AM, et al. Inflammatory mediators, muscle and functional performance of community-dwelling elderly women. Arch Gerontol Geriatr. 2014;59:549–53.
11. Santos MILAS, Gomes WF, Pereira DS, et al. Muscle strength, muscle balance, physical function and plasma interleukin-6 (IL-6) levels in elderly women with knee osteoarthritis (OA). Arch Gerontol Geriatr. 2011;52:322–6.
12. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10:319–29.
13. Schaap LA, Pluijm SMF, Deeg D, et al. Higher Inflammatory Marker Levels and Functional Status in community-dwelling elderly women. J Gerontol A Biol Sci Med Sci. 2009;64A:1183–9.
14. Schalk BW, Deeg DJ, Penninx BW, et al. Serum albumin and muscle strength: a longitudinal study in older men and women. J Gerontol A Biol Sci Med Sci. 2015;70:1331–8.
15. Visser M, Kritchevsky SB, Newman AB, et al. Lower serum albumin concentration and change in muscle mass: the health, aging and body composition study. Am J Clin Nutr. 2005;82:531–7.
16. Kim MW, Lim JY, Oh SH. Mortality prediction using serum biomarkers and various clinical risk scales in community-acquired pneumonia. Scand J Clin Lab Invest. 2017;77:486–92.
17. Coto Montes A, Boga JA, Bermejo Millo C, et al. Potential early biomarkers of sarcopenia among independent older adults. Maturitas. 2017;104:117–22.
18. Bano G, Trevisan C, Carnaro S, et al. Inflammation and sarcopenia: a systematic review and meta-analysis. Maturitas. 2017;105:10–5.
19. Mello De K, Margutti M, Schuch NJ, et al. Inflammatory markers, sarcopenia and its diagnostic criteria among the elderly: a systematic review. Rev Bras Geriatr Gerontol, Rio de Janeiro. 2017;20:441–5.
20. Polstein MF, Polstein SE, McHugh PR. “mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
21. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged: The index of ADL: A standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9.
22. Jou JM, Lewis SM, Briggs C, et al. ICSh review of the measurement of the erythrocyte sedimentation rate. Int J Lab Hematol. 2011;33:125–32.
23. Peel NM, Kuys SS, Klein K. Gait speed as a measure in geriatric assessment in clinical settings: a systematic review. J Gerontol A Biol Sci Med Sci. 2013;68:39–46.

24. Podsiadlo D, Richardson S. The timed "up & go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142–8.

25. Bohannon RW. Test-retest reliability of the five-repetition sit-to-stand test: a systematic review of the literature involving adults. J Strength Cond Res. 2011;25:3205–7.

26. Reijnierse EM, de Jong N, Trappenburg MC, et al. Assessment of maximal handgrip strength: how many attempts are needed? J Cachexia Sarcopenia Muscle. 2017;8:666–74.

27. Ling CH, de Craen AJ, Slagboom PE, et al. Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population. Clin Nutr. 2011;30:610–5.

28. Curcio F, Ferro G, Basile C, et al. Biomarkers in sarcopenia: a multifactorial approach. Exp Gerontol. 2016;85:1–8.

29. Perna S, Peroni G, Farka MA, et al. Sarcopenia and sarcopenic obesity in comparison: prevalence, metabolic profile, and key differences. A cross-sectional study in Italian hospitalized elderly. Aging Clin Exp Res. 2017;29:1249–58.

30. Ferrari R, Caram LMO, Faganello MM, et al. Relation between systemic inflammatory markers, peripheral muscle mass, and strength in limb muscles in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;10:1553–8.

31. Visser M, Pahor M, Taaffe DR, et al. Relationship of Interleukin-6 and tumor necrosis factor-α with muscle mass and muscle strength in elderly men and women: the health ABC study. J Gerontol A Biol Sci Med Sci. 2002;57:M326–M32.

32. Cacciatore F, Della-Morte D, Basile C, et al. Butyrylcholinesterase is related to muscle mass and strength. A new biomarker to identify elderly subjects at risk of sarcopenia. Biomark Med. 2015;9:669–78.

33. Dalle S, Rossmeislova L, Koppo K. The role of inflammation in age-related sarcopenia. Front Physiol. 2017;8:1045.

34. Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol. 2016;229:R67–81.

35. Riley LK, Rupert J. Evaluation of patients with leukocytosis. Am Fam Physician. 2015;92:1004–11.

36. Michaud M, Balard L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14:877–82.

37. Kalinovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev. 2017;35:200–21.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author/s: 
van Atteveld, VA; Van Ancum, JM; Reijnierse, EM; Trappenburg, MC; Meskers, CGM; Maier, AB

Title: 
Erythrocyte sedimentation rate and albumin as markers of inflammation are associated with measures of sarcopenia: a cross-sectional study

Date: 
2019-08-27

Citation: 
van Atteveld, VA; Van Ancum, JM; Reijnierse, EM; Trappenburg, MC; Meskers, CGM; Maier, AB, Erythrocyte sedimentation rate and albumin as markers of inflammation are associated with measures of sarcopenia: a cross-sectional study, BMC GERIATRICS, 2019, 19 (1)

Persistent Link: 
http://hdl.handle.net/11343/234148

File Description: 
Published version